ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 238

Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors

Ayako Nishino1,2,3, Shinya Kawashiri2,3, Tamami Yoshitama2, Nobutaka Eiraku2, Naoki Matsuoka2, Yukitaka Ueki2, Akitomo Okada2, Hiroaki Hamada2, Toshihiko Hidaka2, Shuji Nagano2, Tomomi Tsuru2, Keita Fujikawa2, Yojiro Arinobu2, Yoshifumi Tada2, Yasuhiro Nagata1 and Atsushi Kawakami2,4, 1Center for Comprehensive Community Care Education, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort study group, Nagasaki, Japan, 3Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki City, Japan

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biologic drugs, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 5, 2017

Title: Imaging of Rheumatic Diseases Poster I

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Efficacy of cycling of TNF inhibitors, judged by composite measures, is inferior to non-TNF biologics in patients with RA inadequate response to previous TNF inhibitors (TNF-IR patients). Ultrasonography (US) is a non-invasive imaging method to evaluate activity of synovitis more accurately than physical examinations, however, no previous reports have examined comparative efficacy of alternate TNF inhibitors or non-TNF biologics in RA patients inadequate response to previous TNF inhibitors by US. The aim of this study is to determine whether US find the difference of efficacy in switching to cycling TNF inhibitors compared to non-TNF biologics in TNF-IR patients.

Methods: We have investigated the above-mentioned comparison by the administrated RA patients in Kyushu multicenter rheumatoid arthritis ultrasound prospective observational cohort in which bilateral 22 wrists and finger joints were semi-quantitatively examined every 3 months by grey-scale (GS) and power Dopper (PD) from 0 to 3. US disease activity was determined as sum of GS or PD score (total GS score or PD score; 0-66, respectively). Among the 223 patients who registered and completed the first 12 months observation, thirty-nine subjects were classified as switched to alternate TNF inhibitors (N = 11) or non-TNF biologics (N = 28) as second bDMARDs. We compared the efficacy of alternate TNF inhibitors group with non-TNF biologics group by US for 12 months using LOCF analysis.

Results: The characteristic of both groups at study entry was comparable including DAS28-ESR, duration of diseases, positivity of ACPA or RF and sum of GS and PD score. Drug retention rate at 12 months was superior in non-TNF biologics group compared to alternate TNF inhibitors group. Accordingly, sum of US score, especially PD score, clearly decreased in non-TNF biologics group whereas did poorly change in alternate TNF inhibitors group (Fig. 1). Change of DAS28-ESR was also more prominent in non-TNF biologics group compared to alternate TNF inhibitors group.

Conclusion: Our data confirm the previous clinical finding by US, especially PDUS, that switching to non-TNF biologics is more effective than cycling TNF inhibitors as a second choice of bDMARDs in TNF-IR patients.  

 

 


Disclosure: A. Nishino, None; S. Kawashiri, None; T. Yoshitama, None; N. Eiraku, None; N. Matsuoka, None; Y. Ueki, None; A. Okada, None; H. Hamada, None; T. Hidaka, None; S. Nagano, None; T. Tsuru, None; K. Fujikawa, None; Y. Arinobu, None; Y. Tada, None; Y. Nagata, None; A. Kawakami, None.

To cite this abstract in AMA style:

Nishino A, Kawashiri S, Yoshitama T, Eiraku N, Matsuoka N, Ueki Y, Okada A, Hamada H, Hidaka T, Nagano S, Tsuru T, Fujikawa K, Arinobu Y, Tada Y, Nagata Y, Kawakami A. Power Dopper Ultrasonography Detects Superior Efficacy of Non-TNF Biologics Compared to Cycling of TNF Inhibitors in RA Patients Inadequate Response to First TNF Inhibitors [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/power-dopper-ultrasonography-detects-superior-efficacy-of-non-tnf-biologics-compared-to-cycling-of-tnf-inhibitors-in-ra-patients-inadequate-response-to-first-tnf-inhibitors/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/power-dopper-ultrasonography-detects-superior-efficacy-of-non-tnf-biologics-compared-to-cycling-of-tnf-inhibitors-in-ra-patients-inadequate-response-to-first-tnf-inhibitors/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology